Table 5.
Analyses of Covariance examining learning slope, Trial One, and total learning performances based on APOE ε4 status
| APOE ε4 status Mean (SD) |
F value | p value | η 2 | ||
|---|---|---|---|---|---|
| APOE ε4 Positive | APOE ε4 Negative | ||||
| HVLT-R LR | 0.35 (0.2) | 0.55 (0.4) | 18.97 | <.001 | .14 |
| BVMT-R LR | 0.30 (0.3) | 0.51 (0.3) | 19.80 | <.001 | .15 |
| Aggregate HVLT-R/BVMT-R LR | 0.33 (0.2) | 0.54 (0.3) | 28.15 | <.001 | .20 |
| RBANS List Learning LR | 0.43 (0.3) | 0.61 (0.3) | 12.18 | .001 | .10 |
| RBANS Story Memory LR | 0.41 (0.3) | 0.62 (0.3) | 17.30 | <.001 | .13 |
| Aggregate RBANS LR | 0.41 (0.3) | 0.61 (0.3) | 21.07 | <.001 | .15 |
| HVLT-R RLS | 2.59 (1.5) | 3.03 (2.1) | 2.83 | .10 | .02 |
| BVMT-R RLS | 2.52 (2.3) | 3.05 (1.7) | 1.71 | .19 | .02 |
| Aggregate HVLT-R/BVMT-R RLS | 5.11 (2.9) | 6.09 (3.0) | 3.95 | .05 | .03 |
| RBANS List Learning RLS | 2.54 (1.6) | 3.10 (1.5) | 4.02 | .05 | .03 |
| RBANS Story Memory RLS | 2.37 (1.7) | 2.93 (1.9) | 3.85 | .05 | .03 |
| Aggregate RBANS RLS | 4.90 (2.7) | 6.03 (2.4) | 6.38 | .01 | .05 |
| HVLT-R Trial One | 4.06 (2.4) | 5.76 (2.5) | 14.71 | <.001 | .11 |
| BVMT-R Trial One | 2.57 (2.2) | 5.05 (2.8) | 31.98 | <.001 | .22 |
| RBANS List Learning Trial One | 3.73 (1.3) | 4.48 (1.4) | 10.27 | .002 | .08 |
| RBANS Story Memory Trial One | 4.87 (2.8) | 6.6 (2.8) | 12.40 | .001 | .10 |
| HVLT-R Total Recall | 16.63 (7.3) | 22.57 (7.9) | 22.35 | <.001 | .16 |
| BVMT-R Total Recall | 12.06 (7.9) | 20.18 (9.0) | 32.61 | <.001 | .22 |
| RBANS List Learning Total Score | 20.75 (6.3) | 25.71 (6.6) | 23.11 | <.001 | .17 |
| RBANS Story Memory Total Score | 12.00 (5.6) | 16.14 (5.0) | 21.50 | <.001 | .16 |
Note: APOE ε4 = Apolipoprotein ε4 allele, η2 = partial eta squared, HVLT-R = Hopkins Verbal Learning Test – Revised, LR = Learning Ratio, BVMT-R = Brief Visual Memory Test – Revised, RBANS = Repeatable Battery for the Assessment of Neuropsychological Status, and RLS = Raw Learning Score. Significance values reflect p value of learning score differences between patients with positive or negative APOE ε4 status. Effect Sizes were measured using η2 values. A two-tailed alpha level was set at .01 for all analyses.